During the corresponding time, Insight Molecular Diagnostics Inc saw a revenue deteriorated by -53.86 % year on year, sequentially revenue grew by 646.88 %. While revenue at the Insight Molecular Diagnostics Inc 's corporate clients
Insight Molecular Diagnostics Inc's Comment on Sales, Marketing and Customers
The company targets hospitals, transplant centers, and laboratories as initial customers, with test deployment decisions made by medical professionals including surgeons, nephrologists, oncologists, researchers, pathologists, lab directors, medical directors, department heads, lab managers, and chief medical officers. Its primary near-term strategic market is organ transplant, focusing on providing molecular diagnostic test kits for clinical use that decentralize access to organ health testing for transplant patients. The company aims to serve the approximately $2 billion market for kitted transplant rejection testing. Its flagship transplant testing technology, marketed under the GraftAssure brand, includes laboratory-developed tests (LDTs), research-use-only (RUO) kits, and in vitro diagnostic (IVD) kits. These tests are performed on digital PCR instruments manufactured by Bio-Rad Laboratories, Inc. The company maintains a global strategic partnership with Bio-Rad for the development and commercialization of kitted transplant products for clinical use.
Insight Molecular Diagnostics Inc’s Comment on Sales, Marketing and Customers
The company targets hospitals, transplant centers, and laboratories as initial customers, with test deployment decisions made by medical professionals including surgeons, nephrologists, oncologists, researchers, pathologists, lab directors, medical directors, department heads, lab managers, and chief medical officers. Its primary near-term strategic market is organ transplant, focusing on providing molecular diagnostic test kits for clinical use that decentralize access to organ health testing for transplant patients. The company aims to serve the approximately $2 billion market for kitted transplant rejection testing. Its flagship transplant testing technology, marketed under the GraftAssure brand, includes laboratory-developed tests (LDTs), research-use-only (RUO) kits, and in vitro diagnostic (IVD) kits. These tests are performed on digital PCR instruments manufactured by Bio-Rad Laboratories, Inc. The company maintains a global strategic partnership with Bio-Rad for the development and commercialization of kitted transplant products for clinical use.
Sources:
Insight Molecular Diagnostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Insight Molecular Diagnostics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Insight Molecular Diagnostics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2.51 %